{"public_id":"cl_cb3d75118063346ba078b3d65c0814a9","status":"active","superseded_by_public_id":null,"corpus_id":195356417,"text":"The best dimeric designed ankyrin repeat protein, DLD-4, inhibited C. difficile toxin B with an in vitro EC50 of 4 pM, about 330-fold more potent than bezlotoxumab in the same assay.","confidence":0.99,"paper":{"corpus_id":195356417,"title":"Selection and characterization of ultrahigh potency designed ankyrin repeat protein inhibitors of C. difficile toxin B","url":"https://sah.borca.ai/papers/195356417"},"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"origin_summary":{"object_type":"claim","status":"active","confidence":0.99,"origin_kinds":["extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":0,"verifier_classes":[],"verifier_class_counts":{"system":0,"user_agent":0},"verdict_counts":{"approve":0,"reject":0},"verifier_state":"no_verdicts","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","claim.status","claim.confidence"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"concepts":[{"public_id":"co_4649503a1a700faf064485ee27b19264","name":"DLD-4","description":"A dimeric designed ankyrin repeat protein selected as the most potent anti-TcdB binder described in the abstract.","types":["protein inhibitor","therapeutic candidate"],"url":"https://sah.borca.ai/concepts/co_4649503a1a700faf064485ee27b19264"},{"public_id":"co_622640136c7653c22f2da6c4092ea567","name":"C. difficile toxin B","description":"A secreted exotoxin from Clostridium difficile targeted for neutralization in this study.","types":["toxin","bacterial virulence factor"],"url":"https://sah.borca.ai/concepts/co_622640136c7653c22f2da6c4092ea567"},{"public_id":"co_eb547fbf8f6b99bab53b063679ae0607","name":"bezlotoxumab","description":"An FDA-approved monoclonal antibody used here as a comparator anti-TcdB therapeutic.","types":["monoclonal antibody","baseline comparator"],"url":"https://sah.borca.ai/concepts/co_eb547fbf8f6b99bab53b063679ae0607"}],"related_claims":[],"url":"https://sah.borca.ai/claims/cl_cb3d75118063346ba078b3d65c0814a9"}